In the latest trading session, 0.59 million FibroGen Inc (NASDAQ:FGEN) shares changed hands as the company’s beta touched 0.83. With the company’s most recent per share price at $0.42 changing hands around $0.02 or 6.15% at last look, the market valuation stands at $48.39M. FGEN’s current price is a discount, trading about -597.62% off its 52-week high of $2.93. The share price had its 52-week low at $0.18, which suggests the last value was 57.14% up since then. When we look at FibroGen Inc’s average trading volume, we note the 10-day average is 1.07 million shares, with the 3-month average coming to 1.21 million.
Analysts gave the FibroGen Inc (FGEN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended FGEN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. FibroGen Inc’s EPS for the current quarter is expected to be -0.2.
FibroGen Inc (NASDAQ:FGEN) trade information
Instantly FGEN is in green as seen in intraday trades today. With action 30.61%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -52.09%, with the 5-day performance at 30.61% in the green. However, in the 30-day time frame, FibroGen Inc (NASDAQ:FGEN) is 9.66% up. Looking at the short shares, we see there were 4.32 million shares sold at short interest cover period of 3.27 days.
The consensus price target for the stock as assigned by Wall Street analysts is 28, meaning bulls need an upside of 98.5% from its recent market value. According to analyst projections, FGEN’s forecast low is 28 with 28 as the target high. To hit the forecast high, the stock’s price needs a -6566.67% plunge from its current level, while the stock would need to soar -6566.67% for it to hit the projected low.
FibroGen Inc (FGEN) estimates and forecasts
Data shows that the FibroGen Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -63.71% over the past 6 months, a 70.04% in annual growth rate that is considerably higher than the industry average of 16.40%. Year-over-year growth is forecast to reach 20.37% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 24.91M. The company’s revenue for the corresponding quarters a year ago was 27.14M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -8.21%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.23%. The 2024 estimates are for FibroGen Inc earnings to increase by 72.60%.
FGEN Dividends
FibroGen Inc is expected to release its next quarterly earnings report in January.
FibroGen Inc (NASDAQ:FGEN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.85% of FibroGen Inc shares while 55.04% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 55.51%. There are 55.04% institutions holding the FibroGen Inc stock share, with PRIMECAP MANAGEMENT CO/CA/ the top institutional holder. As of 2024-06-30, the company held 13.7964% of the shares, roughly 13.66 million FGEN shares worth $12.19 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 9.0279% or 8.94 million shares worth $7.97 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Horizon Fund-Capital Opportunity Fund and Vanguard Total Stock Market Index Fund. With 3.98 shares estimated at $1.66 million under it, the former controlled 3.95% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.89% of the shares, roughly 2.92 shares worth around $1.22 million.
